Overview

A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects

Status:
RECRUITING
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
A Randomized, Double-Blind, Placebo-Controlled, Single/Multiple-dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BGM0504 Tablets Orally Administered in Healthy and Non-diabetic Overweight or Obese Chinese Subjects.
Phase:
PHASE1
Details
Lead Sponsor:
BrightGene Bio-Medical Technology Co., Ltd.